US Bancorp’s Seres Therapeutics MCRB Stock Holding History

US Bancorp’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12	Closed	-$231	–	4141
2025 Q3	$231	Sell	12 -13	-52%	-$207	﹤0.01%	3933
2025 Q2	$278	Buy	+25	New	+$220	﹤0.01%	4047
2023 Q2	–	Sell	-9	Closed	-$992	–	4073
2023 Q1	$992	Buy	+9	New	+$974	﹤0.01%	3870
2022 Q2	–	Sell	-12	Closed	-$2K	–	4153
2022 Q1	$2K	Sell	12 -2	-14%	-$308	﹤0.01%	3841
2021 Q4	$2K	Buy	14 +2	+17%	+$318	﹤0.01%	3900
2021 Q3	$2K	Buy	12 +10	+500%	+$1.96K	﹤0.01%	3895
2021 Q2	$1K	Buy	+2	New	+$844	﹤0.01%	3921
2018 Q2	–	Sell	-6	Closed	-$1K	–	3658
2018 Q1	$1K	Hold	6	–	–	﹤0.01%	3547
2017 Q4	$1K	Hold	6	–	–	﹤0.01%	3535
2017 Q3	$2K	Hold	6	–	–	﹤0.01%	3435
2017 Q2	$1K	Buy	+6	New	+$1.23K	﹤0.01%	3471

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

US Bancorp's MCRB Position: Q4 2025 in Review

US Bancorp sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 12 shares — an estimated $231 sold.

US Bancorp first reported a position in MCRB in Q2 2017 and held it in 11 quarters. The position peaked at $2K in Q1 2022. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

US Bancorp reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
US Bancorp sold 12 Seres Therapeutics shares in Q4 2025, an estimated $231.
US Bancorp first reported a position in Seres Therapeutics in Q2 2017 and held it in 11 quarters.
US Bancorp's Seres Therapeutics position peaked at $2K in Q1 2022.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.